Hosted on MSN1mon
Novavax climbs as FDA lifts clinical hold on Covid, flu combo trials
Novavax, Inc. (NVAX) Baird 2024 Global Healthcare Conference (Transcript) Novavax in $123.8M settlement with U.K. agency over COVID vaccine deal Novavax stock plunges as FDA puts clinical hold on ...
Axios Vitals on MSN3mon
FDA halts trial of Novavax COVID-flu combo shot
The clinical hold does not impact Novavax's COVID-19 vaccine. The big picture: Pfizer and BioNTech's effort to develop a ...
Novavax Cashes In On Its COVID Albatross -- Challenges Remain (Rating Upgrade)
With its significant cash infusions from offloading its COVID assets, Novavax had just over $1 billion as it exited Q3, 2024.
Nasdaq1mon
NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines
Novavax NVAX announced that it has started dosing participants in the phase III study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.